Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those ...

Ultrasound-detected bursitis and higher baseline BMI are associated with the development of musculoskeletal symptoms in ...

You should watch your symptoms carefully if you have an infection and contact your doctor if you suspect an infection has triggered your psoriasis. Check your body to determine whether a skin ...

Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link between central fat and ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Zoryve foam, 0.3% is a once-daily topical treatment for plaque psoriasis on the body and scalp. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) topical foam ...

In the study, "Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body," published in JAMA Dermatology, researchers conducted a double-blinded, placebo-controlled, randomized clinical trial to ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...